Zacks Research Issues Optimistic Forecast for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Research analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will earn $1.03 per share for the quarter, up from their previous estimate of $1.00. The consensus estimate for Bausch Health Companies' current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies' FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.09 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.37 EPS and FY2026 earnings at $5.05 EPS.

Other analysts have also recently issued reports about the company. Royal Bank of Canada upped their target price on Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a report on Friday, November 1st. Evercore ISI raised shares of Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. Finally, StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Bausch Health Companies has a consensus rating of "Hold" and a consensus price target of $7.75.

Bausch Health Companies Stock Performance

Shares of BHC stock traded up $0.05 on Thursday, hitting $7.39. The company had a trading volume of 828,477 shares, compared to its average volume of 2,754,950. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The firm has a market cap of $2.67 billion, a P/E ratio of -15.40 and a beta of 0.69. The stock's 50-day moving average is $8.35 and its two-hundred day moving average is $7.27.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.10. The company had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies's revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.03 earnings per share.

Institutional Investors Weigh In On Bausch Health Companies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldentree Asset Management LP boosted its position in shares of Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company's stock worth $239,552,000 after purchasing an additional 6,958,717 shares in the last quarter. Bank of Montreal Can raised its stake in Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company's stock worth $31,598,000 after buying an additional 2,685,675 shares during the period. Maple Rock Capital Partners Inc. bought a new position in Bausch Health Companies in the third quarter worth approximately $16,850,000. Mackenzie Financial Corp grew its stake in Bausch Health Companies by 111.0% in the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock valued at $16,612,000 after acquiring an additional 1,252,834 shares during the period. Finally, Clearline Capital LP acquired a new stake in Bausch Health Companies in the second quarter valued at approximately $6,881,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.